In our opinion, we may use XPO1 E571K detection by cfDNA analysis to help pathologists to orient between NSCHL, MGZL and DLBCL, especially in the relapse setting if this variant was already present at diagnosis, despite the lack of specificity of this hotspot mutation [79,80,81]. This evidence concerns the gene XPO1 and diffuse large B-cell lymphoma.